JP2021522247A5 - - Google Patents
Info
- Publication number
- JP2021522247A5 JP2021522247A5 JP2020559442A JP2020559442A JP2021522247A5 JP 2021522247 A5 JP2021522247 A5 JP 2021522247A5 JP 2020559442 A JP2020559442 A JP 2020559442A JP 2020559442 A JP2020559442 A JP 2020559442A JP 2021522247 A5 JP2021522247 A5 JP 2021522247A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- solvate
- phenyl
- pharmaceutical composition
- liver disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662074P | 2018-04-24 | 2018-04-24 | |
| US62/662,074 | 2018-04-24 | ||
| PCT/US2019/028551 WO2019209738A1 (en) | 2018-04-24 | 2019-04-22 | Use of neutrophil elastase inhibitors in liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522247A JP2021522247A (ja) | 2021-08-30 |
| JP2021522247A5 true JP2021522247A5 (enExample) | 2022-04-27 |
Family
ID=68236763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559442A Pending JP2021522247A (ja) | 2018-04-24 | 2019-04-22 | 肝疾患における好中球エラスターゼ阻害薬の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10806735B2 (enExample) |
| EP (1) | EP3784657A4 (enExample) |
| JP (1) | JP2021522247A (enExample) |
| KR (1) | KR20210002573A (enExample) |
| CN (1) | CN113614070A (enExample) |
| AU (2) | AU2019257632A1 (enExample) |
| CA (1) | CA3101274A1 (enExample) |
| IL (1) | IL278207A (enExample) |
| SG (1) | SG11202010521VA (enExample) |
| TW (1) | TW202011965A (enExample) |
| WO (1) | WO2019209738A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| PE20231096A1 (es) | 2020-08-25 | 2023-07-18 | Lilly Co Eli | Polimorfos de un inhibidor de ssao |
| EP4210705A4 (en) * | 2020-09-11 | 2024-11-13 | Terns Pharmaceuticals, Inc. | SOLID DISPERSION FORMULATIONS OF A FXR AGONIST |
| CN114085173B (zh) * | 2021-10-18 | 2024-04-16 | 嘉兴学院 | 一种2-硝基-4-甲砜基苯甲醛的制备方法 |
| CN115976192A (zh) * | 2022-12-02 | 2023-04-18 | 西安华壹健康医学检验实验室有限公司 | 一种用ne基因表达量检测评估脂肪肝的方法 |
| CN117357508B (zh) * | 2023-11-03 | 2024-05-17 | 中山大学孙逸仙纪念医院 | 西维来司他在制备治疗原发性胆汁性胆管炎的药物中的应用 |
| CN119499379B (zh) * | 2024-09-23 | 2025-09-05 | 广东医科大学 | Elane基因作为心力衰竭靶点的制药用途和西维来司他的新用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20120457T1 (hr) * | 2007-12-20 | 2012-06-30 | Bayer Pharma Aktiengesellschaft | 4-(4-cijano-2-tioaril)dihidropirimidinoni i njihova uporaba |
| US9475779B2 (en) * | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| AU2015314830B2 (en) * | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| WO2016050835A2 (en) | 2014-10-02 | 2016-04-07 | Ruprecht-Karls-Universität Heidelberg | Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component |
| MX2017008844A (es) * | 2015-01-09 | 2018-03-14 | Gilead Apollo Llc | Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. |
| CA2980071A1 (en) | 2015-03-18 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile |
| CN107613986A (zh) * | 2015-04-07 | 2018-01-19 | 英特塞普特医药品公司 | 用于组合疗法的药物组合物 |
| WO2017081044A1 (en) | 2015-11-13 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
| GB201608453D0 (en) | 2016-05-13 | 2016-06-29 | Univ Liverpool | Muscle regeneration |
| KR102399254B1 (ko) * | 2016-09-28 | 2022-05-17 | 아이거 바이오파마슈티컬스 인코포레이티드 | 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 |
-
2019
- 2019-04-22 KR KR1020207033317A patent/KR20210002573A/ko not_active Ceased
- 2019-04-22 CN CN201980040583.1A patent/CN113614070A/zh active Pending
- 2019-04-22 AU AU2019257632A patent/AU2019257632A1/en not_active Abandoned
- 2019-04-22 SG SG11202010521VA patent/SG11202010521VA/en unknown
- 2019-04-22 US US16/390,970 patent/US10806735B2/en active Active
- 2019-04-22 CA CA3101274A patent/CA3101274A1/en active Pending
- 2019-04-22 JP JP2020559442A patent/JP2021522247A/ja active Pending
- 2019-04-22 WO PCT/US2019/028551 patent/WO2019209738A1/en not_active Ceased
- 2019-04-22 EP EP19793755.0A patent/EP3784657A4/en not_active Withdrawn
- 2019-04-24 TW TW108114343A patent/TW202011965A/zh unknown
-
2020
- 2020-09-21 US US17/027,617 patent/US20210069192A1/en not_active Abandoned
- 2020-10-21 IL IL278207A patent/IL278207A/en unknown
-
2024
- 2024-10-28 AU AU2024227697A patent/AU2024227697A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| CN104918613B (zh) | 通过给予秋水仙碱衍生物治疗或预防心血管事件 | |
| JP2023541430A5 (enExample) | ||
| JP5767122B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| US20240325356A1 (en) | Prophylactic and therapeutic drug for nonalcoholic fatty liver disease | |
| JP2015528471A5 (enExample) | ||
| JP2009511450A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2019515909A5 (enExample) | ||
| JP2024095711A (ja) | 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール | |
| JP2020500868A5 (enExample) | ||
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2022517902A5 (enExample) | ||
| JP2005527575A5 (enExample) | ||
| CN110755432A (zh) | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 | |
| JP2025517509A5 (enExample) | ||
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| FI3941466T3 (fi) | Vafidemstat epävakaan persoonallisuushäiriön ei-aggressiivisen oireiden hoitoon | |
| JP2009532494A5 (enExample) | ||
| RU2022107481A (ru) | Применение ингибитора эластазы нейтрофилов при заболеваниях легких | |
| RU2021130172A (ru) | Способы лечения пограничного расстройства личности | |
| RU2020109167A (ru) | Способы лечения изменений поведения | |
| RU2023109542A (ru) | Способы лечения заболеваний, связанных с рибонуклеотидредуктазой, ингибитором рибонуклеотидредуктазы |